Key result
In a rat model of arterial thrombosis, the thromboxane receptor antagonist SQ 30,741 decreased average thrombus weight by 57%, whereas aspirin alone did not significantly affect thrombus weight.
Why the study?
The relative antithrombotic activities of aspirin, a thromboxane receptor antagonist, and heparin in arterial thrombosis were not fully characterized.
Does SQ 30,741, aspirin, or heparin reduce thrombus weight in a rat model of arterial thrombosis?
Does SQ 30,741, aspirin, or heparin reduce thrombus weight in a rat model of arterial thrombosis?
In a rat model of arterial thrombosis, a thromboxane receptor antagonist and high-dose heparin significantly reduced thrombus weight, whereas aspirin alone was ineffective.
Answers are grounded in this paper and cite their sources.
TP-receptor antagonism reduced rat arterial thrombosis where aspirin failed; leaves open human translation and comparative efficacy.
The antithrombotic activities of aspirin, the thromboxane (Tx) A2/prostaglandin endoperoxide-receptor (TP-receptor) antagonist, SQ 30,741, and heparin were determined in anesthetized rats. Heparin (3 doses of 50, 300 U/kg), aspirin (1 and 10 mg/kg), SQ 30,741 (1 mg/kg + 1 mg/kg/h), or the combination of SQ 30,741 and aspirin (10 mg/kg) was administered intravenously before inducing occlusive thrombosis with 0.1-mA stimulation of the intimal surface of the carotid artery. Light and electron microscopy revealed the thrombi to be composed predominantly of platelets enmeshed in a fibrin network. Heparin (300 U/kg), SQ 30,741 and SQ 30,741 + aspirin decreased average thrombus weight by 54, 57 and 39%, respectively. These treatments also reduced the incidence of occlusion and improved carotid blood flow during thrombosis. In contrast, aspirin alone (1 and 10 mg/kg) and the lower heparin dose (50 U/kg) did not significantly affect thrombus weight or carotid blood flow. To verify adequate drug dosage, pharmacological activities were characterized ex vivo in separate rats. Aspirin (10 mg/kg) inhibited maximum thromboxane (Tx) B2 production in whole blood by 99 +/- 1% and SQ 30,741 blocked 96% of platelet TP-receptors. Heparin increased the activated partial thromboplastin time (APTT) partially at 50 U/kg (approximately 3-fold) and maximally at 300 U/kg (> 10-fold). These experiments demonstrate the contribution of platelet and coagulation mechanisms to a thrombosis model which is sensitive to a TP-receptor antagonist, but not aspirin.
No takes yet. Share an insight, caveat, or question.
Schumacher et al. (2009) studied Experimental arterial thrombosis. SQ 30,741, aspirin, and heparin vs. Aspirin alone or lower heparin dose was evaluated on Thrombus weight, incidence of occlusion, and carotid blood flow. In a rat model of arterial thrombosis, the thromboxane receptor antagonist SQ 30,741 decreased average thrombus weight by 57%, whereas aspirin alone did not significantly affect thrombus weight.
Synapse has enriched 10 related papers. Consider them for comparative context: